The abstract is read at the publisher; the summary is JClub's.
Early-stage, presymptomatic type 1 diabetes mellitus is defined by having two or more islet autoantibodies, enabling detection years before hyperglycaemia and insulin need.
- Why it matters: The presymptomatic window offers a chance to intervene earlier, lowering diabetic ketoacidosis risk at diagnosis and improving follow-up, education, and access to disease-modifying options and trials.
- What they did: This Review compares screening strategies, from islet autoantibody screening in high-risk individuals to general-population screening, and evaluates clinical, logistical, economic, and ethical considerations for routine health care.
- The result: Successful large-scale screening depends on sustainable integration, with unresolved issues including cost-effectiveness, equitable access to follow-up and therapies, and harmonized care pathways.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.